Newsroom

Our latest developments

Orca Bio’s announcements and press releases

August 2, 2022:

Orca Bio Announces the Precision-T Phase 3 Study is Open and Enrolling Patients at Transplant Centers Across the U.S.

May 12, 2022:

Orca Bio to Present New Clinical Data on Orca-T at the European Hematology Association 2022 Congress

April 25, 2022:

Orca Bio Presents Positive Data Reinforcing Clinical Profile and Manufacturing Reliability of Orca-T at 2022 Transplantation & Cellular Therapy ASTCT and CIBMTR Tandem Meetings

January 06, 2022:

Orca Bio to Present at the 40th Annual J.P. Morgan Healthcare Conference

December 11, 2021:

Positive Clinical Results from More than 100 Patients Treated with Orca Bio’s Lead Investigational High Precision Cell Therapy Presented at 63rd ASH Annual Meeting

November 4, 2021:

Orca Bio to Present New Clinical Data on Orca-T at the 63rd American Society of Hematology Annual Meeting

February 11, 2021:

Orca Bio Announces Updated Orca-T Clinical Data Presented at the 2021 TCT Meetings of ASTCT and CIBMTR

January 6, 2021:

Orca Bio to Present at the 39th Annual J.P Morgan Healthcare Conference

December 6, 2020:

First Clinical Data From Ongoing Orca-T Trial Shows Significantly Improved 12-Month GRFS in Blood Cancer Patients Receiving an HSCT

November 4, 2020:

Orca Bio Announces Oral Presentation of Orca-T Clinical Data at the 62nd ASH Annual Meeting

October 14, 2020:

Orca Bio Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for Orca-T

September 2, 2020:

Orca Bio and Lyell Immunopharma Announce Research Partnership

June 17, 2020:

Orca Bio Emerges With Nearly $300 Million to Transform Allogeneic Cell Therapy

Orca Bio's fact sheets

March 22, 2022:

Orca Bio Corporate Overview

For media inquiries,

contact us at: